5 completed, 2 recruiting, 1 terminated. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
Follow VX-561: new trials by email Literature Review of VX-561 trials Research Report on VX-561
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants VX-272, Placebo, Tezacaftor - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 160 | 2026-02-25 | 2026-09-23 |
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis VX-828, Placebo, Itraconazole - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 165 | 2023-12-12 | 2026-08-10 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX-121, TEZ, VX-561 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 87 | 2019-04-30 | 2023-04-20 |
| A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis VX-561, IVA, Placebo - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 77 | 2019-04-17 | 2022-01-25 |
| A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis VX-659, TEZ/IVA, IVA - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 124 | 2017-08-08 | 2021-04-22 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations VX-561, Placebo, IVA - Cystic Fibrosis | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 11 | 2016-12-01 | 2020-08-26 |
Cystic Fibrosis (8)
Vertex Pharmaceuticals Incorporated (8)
United States (8) · Netherlands (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Germany (2) · Ireland (2) · Israel (1) · Portugal (1)
PMID 33331662, PMID 36842446, PMID 37983082, PMID 30334692, PMID 30334693
2016 (1), 2017 (1), 2018 (1)